Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PPH
PPH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PPH News
Novo Nordisk's Stock Decline Highlights the Side Effect of GLP-1 Investments: ETF Concentration Risk
Nov 24 2025
Benzinga
Hedge Funds Acquire Eli Lilly, United Healthcare, and Others, Renewing Focus on Healthcare ETFs
Nov 17 2025
Benzinga
Eli Lilly Dominance: The Impact of a Single Stock on Pharma ETF Performance
Nov 15 2025
Benzinga
Pharma ETFs Gain Attention After Strong Q3 Earnings Reports
Nov 14 2025
NASDAQ.COM
Eli Lilly CEO Criticizes PBM 'Rent-Seeking', Claims They Increased Insulin List Prices to $275: 'We Can Easily Bypass Them'
Nov 12 2025
Benzinga
Is Trump's MFN Policy Targeting Pharma ETFs?
Nov 10 2025
NASDAQ.COM
Eli Lilly Strengthens Position in $150B Obesity Drug Competition Amid Novo and Pfizer Rivalry — Potential Benefits for ETFs
Oct 30 2025
Benzinga
AstraZeneca Joins Other Drugmakers in Deal with Trump; Stock Declines Yet Outperforms Market.
Oct 10 2025
MarketWatch
Most Active Stocks After Hours on October 6, 2025: SOFI, BMEA, PPH, NVDA, CSCO, CMCSA
Oct 06 2025
NASDAQ.COM
Pfizer and TrumpRx Partnership Propels Big Pharma to Historic Surge
Oct 04 2025
SeekingAlpha
Economist Warns Trump's Full Drug Tariff Will Burden Americans, Not Foreign Companies
Sep 29 2025
Benzinga
Pharma Stocks Rise as Trump's Tariff Decision May Benefit the Industry
Sep 26 2025
MarketWatch
Pharmaceutical Industry Recovers Despite Trump's New Tariff Warning
Sep 26 2025
SeekingAlpha
Mark Cuban Reveals How Wholesalers Coerce Pharmacies into Nearly Exclusive Agreements, Highlighting PBMs' 'Stranglehold' on Medication Costs
Sep 08 2025
Benzinga
NVO Receives FDA Approval for MASH Therapy: ETFs Expected to Benefit
Aug 19 2025
NASDAQ.COM
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Aug 08 2025
NASDAQ.COM
Show More News
